Awards, Honors, and Grants


January 25, 2023

Menard Awarded $4M Novo Nordisk Foundation Grant for Clinical Trial on Preventing Leg Amputation with Critical Limb Ischemia

Matthew T. Menard, MD


Matthew T. Menard, MD, co-director of Endovascular Surgery in the Division of Vascular and Endovascular Surgery, was awarded a $4 million grant from the Novo Nordisk Foundation for a multi-institutional clinical trial to determine the optimal treatment to avoid leg amputation in patients with chronic limb threatening ischemia (CLTI), a condition that occurs when blood flow to the extremities is blocked or severely reduced.

Menard is principal investigator of the recently completed, National Institutes of Health-sponsored BEST-CLI trial — short for the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia — which compared treatment efficacy, functional outcomes, quality of life and cost-effectiveness of surgical bypass versus endovascular revascularization as treatment strategies for CLTI. With this funding, Menard will collaborate with colleagues at Boston Medical Center, Massachusetts General Hospital and Kolding/Lillebælt Hospital in Denmark to extend the analysis of this landmark international trial, establish a core angiographic imaging laboratory at BWH and investigate the health economics of CLTI care globally.

In addition to his work as a vascular and endovascular surgeon, Menard is the director of the Vascular and Endovascular Fellowship Program, an associate professor of Surgery at Harvard Medical School and the author of over 95 peer-reviewed publications and book chapters. His clinical interests include aortic aneurysms, arterial occlusive disease, cerebrovascular disease, thoracic outlet syndrome and venous compression syndromes. 

Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. Its vision is to improve people’s health and the sustainability of society and the planet, and its mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.